Cohort overview and response to DLI
| . | All . | Continuous GVL . | Intermittent GVL . | No response . |
|---|---|---|---|---|
| N | 23 | 10 | 7 | 6 |
| Age at DLI, y | 46 (22-72) | 49 (22-63) | 39 (24-72) | 45.5 (23-65) |
| Sex, male | 13 (57) | 7 (70) | 3 (43) | 3 (50) |
| Disease, AML | 17 (74) | 6 (60) | 7 (100) | 4 (67) |
| Disease risk, adverse/high risk | 8 (35) | 3 (30) | 2 (29) | 3 (50) |
| DLI trigger | ||||
| Cytologic/histologic relapse | 12 (52) | 5 (50) | 3 (43) | 4 (67) |
| Molecular relapse | 5 (22) | 3 (30) | 1 (14) | 1 (17) |
| Increased host chimerism | 6 (26) | 2 (20) | 3 (43) | 1 (17) |
| CTx pre-DLI | 11 (48) | 5 (50) | 3 (43) | 3 (50) |
| First DLI, mo post-aHSCT | 11 (4.1-75.7) | 16.7 (5.5-75.7) | 11.5 (4.1-29.4) | 9.2 (4.6-17.1) |
| Dose first DLI, CD3+/kg BW | 5 × 10E6 (5 × 10E5-2.5 × 10E7) | 5.5.×10E6 (5 × 10E5-1.2 × 10E7) | 1 × 10E7 (1 × 10E6-2.5 × 10E7) | 3.5 × 10E6 (1 × 10E6-1 × 10E7) |
| Total number of DLI | 2 (1-7) | 2 (1-4) | 3 (1-7) | 2 (1-4) |
| First GVL, mo post-DLI | 0.6 (0.4-4.4) | 0.7 (0.5-1.7) | — | |
| Relapse, mo post-DLI | — | 13.9 (3.7-15.0) | 0.9 (0.2-5.9) | |
| OS at 36 mo post-DLI, mo | 16.6 (1.7-36.0) | 36.0 (2.6-36.0) | 18.6 (8.5-36.0) | 5.0 (1.7-16.6) |
| Patients alive at 36 mo post DLI | 8 (35) | 6 (60) | 2 (29) | 0 (0) |
| . | All . | Continuous GVL . | Intermittent GVL . | No response . |
|---|---|---|---|---|
| N | 23 | 10 | 7 | 6 |
| Age at DLI, y | 46 (22-72) | 49 (22-63) | 39 (24-72) | 45.5 (23-65) |
| Sex, male | 13 (57) | 7 (70) | 3 (43) | 3 (50) |
| Disease, AML | 17 (74) | 6 (60) | 7 (100) | 4 (67) |
| Disease risk, adverse/high risk | 8 (35) | 3 (30) | 2 (29) | 3 (50) |
| DLI trigger | ||||
| Cytologic/histologic relapse | 12 (52) | 5 (50) | 3 (43) | 4 (67) |
| Molecular relapse | 5 (22) | 3 (30) | 1 (14) | 1 (17) |
| Increased host chimerism | 6 (26) | 2 (20) | 3 (43) | 1 (17) |
| CTx pre-DLI | 11 (48) | 5 (50) | 3 (43) | 3 (50) |
| First DLI, mo post-aHSCT | 11 (4.1-75.7) | 16.7 (5.5-75.7) | 11.5 (4.1-29.4) | 9.2 (4.6-17.1) |
| Dose first DLI, CD3+/kg BW | 5 × 10E6 (5 × 10E5-2.5 × 10E7) | 5.5.×10E6 (5 × 10E5-1.2 × 10E7) | 1 × 10E7 (1 × 10E6-2.5 × 10E7) | 3.5 × 10E6 (1 × 10E6-1 × 10E7) |
| Total number of DLI | 2 (1-7) | 2 (1-4) | 3 (1-7) | 2 (1-4) |
| First GVL, mo post-DLI | 0.6 (0.4-4.4) | 0.7 (0.5-1.7) | — | |
| Relapse, mo post-DLI | — | 13.9 (3.7-15.0) | 0.9 (0.2-5.9) | |
| OS at 36 mo post-DLI, mo | 16.6 (1.7-36.0) | 36.0 (2.6-36.0) | 18.6 (8.5-36.0) | 5.0 (1.7-16.6) |
| Patients alive at 36 mo post DLI | 8 (35) | 6 (60) | 2 (29) | 0 (0) |
Given is the median (range) for continuous variables and the absolute number (%) for categorical variables.
AML, acute myeloid leukemia; BW, body weight; CTx, chemotherapy; OS, overall survival. —, not applicable.